SCHEMBL4294550

SCHEMBL4294550

O=C(Nc1ccn(CCO)n1)C(Cc1c(F)cccc1F)n1ncc(Oc2c(F)cccc2F)cc1=O

nearest known ligand 0.40

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
GCK P35557 5/20 0.40
STIM1 Q13586 2/20 0.35
ORAI1 Q96D31 2/20 0.35
EGFR P00533 1/20 0.34
SMN1; SMN2 Q16637 3/20 0.31
NPC1 O15118 2/20 0.31
RAB9A P51151 2/20 0.31
LMNA P02545 1/20 0.31
HTT P42858 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31
ORAI3 Q9BRQ5 1/20 0.31
HDAC8 Q9BY41 1/20 0.31
NFKB1 P19838 1/20 0.30
NFKB2 Q00653 1/20 0.30
RELA Q04206 1/20 0.30
POLB P06746 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4289059 0.92 HDAC8 (0.40) GCKSMN1; SMN2NPC1RAB9ALMNA
SCHEMBL4288515 0.90 STIM1 (0.33) GCKSTIM1ORAI1EGFRSMN1; SMN2
SCHEMBL4288522 0.90 STIM1 (0.33) GCKSTIM1ORAI1EGFRSMN1; SMN2
SCHEMBL4290688 0.90 STIM1 (0.35) GCKSTIM1ORAI1EGFRSMN1; SMN2
SCHEMBL4290692 0.90 STIM1 (0.35) GCKSTIM1ORAI1EGFRSMN1; SMN2
SCHEMBL4295913 0.90 STIM1 (0.35) GCKSTIM1ORAI1EGFRSMN1; SMN2
SCHEMBL1064565 0.89 GCK (0.39) GCKSTIM1ORAI1EGFRSMN1; SMN2
SCHEMBL1064873 0.89 GCK (0.39) GCKSTIM1ORAI1EGFRSMN1; SMN2
SCHEMBL1063209 0.89 GCK (0.39) GCKSTIM1ORAI1EGFRSMN1; SMN2
SCHEMBL1065304 0.88 GCK (0.38) GCKSTIM1ORAI1EGFRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8258134-B2 Pyridazinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2012-09-04 US claimed
US-8258134-B2 Pyridazinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2012-09-04 US disclosed
US-8258134-B2 Pyridazinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2012-09-04 US disclosed
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 US disclosed
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS GCK, GCKR, PDXK GCK 1/4885STIM1 4449/4885ORAI1 4800/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.